Trial Design Challenges when Combining Medication and Parent Training in Children with Pervasive Developmental Disorders

Autor/inn/en	Scahill, Lawrence; Aman, Michael G.; McDougle, Christopher J.; Arnold, L. Eugene; McCracken, James T.; Handen, Benjamin; Johnson, Cynthia; Dziura, James; Butter, Eric; Sukhodolsky, Denis; Swiezy, Naomi; Mulick, James; Stigler, Kimberly; Bearss, Karen; Ritz, Louise; Wagner, Ann; Vitiello, Benedetto
Titel	Trial Design Challenges when Combining Medication and Parent Training in Children with Pervasive Developmental Disorders
Quelle	In: Journal of Autism and Developmental Disorders, 39 (2009) 5, S.720-729 (10 Seiten) PDF als Volltext Verfügbarkeit
Sprache	englisch
Dokumenttyp	gedruckt; online; Zeitschriftenaufsatz
ISSN	0162-3257
DOI	10.1007/s10803-008-0675-2
Schlagwörter	Intervention; Pervasive Developmental Disorders; Parent Education; Drug Therapy; Parent Participation; Program Design; Comparative Analysis; Compliance (Psychology); Aggression; Psychological Patterns; Self Destructive Behavior; Adjustment (to Environment); Antisocial Behavior; Symptoms (Individual Disorders) + Suchen Sie Ihr Suchwort? Parents education; Elternbildung; Elternschule; Elternmitwirkung; Programme design; Programmaufbau; Programmplanung; Self destrucive behaviour; Selbstzerstörung; Psychiatrische Symptomatik
Abstract	This paper presents the rationale for a 24-week, randomized trial designed to test whether risperidone plus structured parent training would be superior to risperidone only on measures of noncompliance, irritability and adaptive functioning. In this model, medication reduces tantrums, aggression and self-injury; parent training promotes improvement in noncompliance and adaptive functioning. Thus, medication and parent training target related, but separate, outcomes. At week 24, the medication was gradually withdrawn to determine whether subjects in the combined treatment group could be managed on a lower dose or off medication without relapse. Both symptom reduction and functional improvement are important clinical treatment targets. Thus, experimental evidence on the beneficial effects of combining pharmacotherapy and exportable behavioral interventions is needed to guide clinical practice. (As Provided).
Anmerkungen	Springer. 233 Spring Street, New York, NY 10013. Tel: 800-777-4643; Tel: 212-460-1500; Fax: 212-348-4505; e-mail: service-ny@springer.com; Web site: http://www.springerlink.com
Erfasst von	ERIC (Education Resources Information Center), Washington, DC
Update	2017/4/10